View Online | Sign Up

Greetings, OAC Community! We are thrilled to share that this month has been marked by significant strides in reshaping the landscape of obesity care. From taking OAC Action on Capitol Hill to co-hosting an impactful Obesity Care Week, our commitment to transforming the way we care about obesity is stronger than ever before. Keep reading for a recap of our achievements and the noteworthy progress we've made, as well as upcoming events and how you can make a difference with us. 

Listen Now: The Health Advocates Podcast Features OAC Board Chair Kristal Hartman

In this podcast episode of The Health Advocates, presented by the Global Healthy Living Foundation (GHLF), OAC Board Chair Kristal Hartman shares her patient journey, including her bariatric surgery in 2014, which she describes as the hardest and best decision she ever made for herself. She also shares how she fights for access to quality, compassionate, and affordable care for all people living with the chronic disease of obesity.

Listen now.

Good Morning America interviews OAC VP & COO James Zervios

Ahead of this year’s Oscars, pharmaceutical company Eli Lilly shook things up with a bold new commercial, bringing awareness to a hot topic in the media that poses a significant issue – the misuse of GLP-1 medications for cosmetic purposes among celebrities. The commercial emphasizes that these medications are intended solely as a treatment option for people affected by obesity. In an interview with Good Morning America, OAC’s Vice President and Chief Operating Officer, James Zervios, further highlights the important role these medications play as a safe and effective option for obesity treatment. 

Watch the interview.

Watch the Replay! OAC Health Talk: Let’s Talk About Sex (And Bariatric Surgery)! 

In this episode of OAC Health Talks, bariatric surgeon Corrigan McBride, MD, DABOM, FACS, FASMBS, discusses what makes a healthy romantic relationship and how bariatric surgery can affect relationships, sexual function, and fertility. She also offers practical strategies for building a support system.

Watch now. 

OAC Releases Statement on Food and Drug Administration’s (FDA) Update to Wegovy® Label

Wegovy® has been FDA-approved for cardiovascular risk reduction in people with overweight or obesity and an established cardiovascular disease. The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy® statistically significantly reduced the risk of major adverse cardiovascular events. Obesity care is both life-saving and life-changing, and this FDA label change demonstrates this clearly.

Read our full statement on the OAC Blog.

Introducing the Action Fund: Your Opportunity to Drive Real Change!

Join us in our mission to create a world free of bias and ensure access to comprehensive, compassionate care for all individuals affected by obesity. The Action Fund is our latest initiative, designed to empower supporters like you to make a direct impact on our advocacy efforts.

With your generous contributions to the Action Fund, we can amplify our advocacy initiatives and educate the public about our ongoing work. This funding will allow us to train our Community members on how to stand up for themselves and the obesity community, equipping them with the tools and resources they need to drive meaningful change. Together, we can empower individuals to advocate for obesity to be treated the same as other chronic diseases and transform the landscape of obesity care.

Give today. 

Was this email forwarded to you? Subscribe to our mailing list!